<DOC>
	<DOC>NCT01302041</DOC>
	<brief_summary>To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.</brief_summary>
	<brief_title>A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy) Asymptomatic from prostate cancer Noncastrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening PSA ≥ 2 ng/mL at screening Has previously or is currently receiving: Hormonal therapy with intent to treat prostate cancer Systemic glucocorticoids Chemotherapy with the intent to treat prostate cancer Opiate analgesics for pain from prostate cancer Radiation therapy for treatment of the primary tumor or metastases Has history of known or suspected brain or skull metastases or leptomeningeal disease Has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or transient ischemic attack Clinically significant cardiovascular disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bone turnover</keyword>
	<keyword>hormone-naïve</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>